Добірка наукової літератури з теми "PET/CT Scan"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "PET/CT Scan".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "PET/CT Scan":
1
Rippstein, Karen. "PET/CT Scan." Journal of Poetry Therapy 22, no. 2 (June 2009): 115–16. http://dx.doi.org/10.1080/08893670903072943.
2
Yi, J., S. Kim, S. Lee, S. Park, Y. Ko, J. Choi, and W. Kim. "Clinical usefulness of PET/CT in initial staging and response evaluation of primary gastric lymphoma." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e19541-e19541. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e19541.
Анотація:
e19541 Background: Positron emission tomography (PET)/computed tomography (CT) scan has a well-established role in the management of non-Hodgkin's lymphoma (NHL). However, in case of the primary gastric lymphoma, which is the most frequent extranodal NHL, the role of PET/CT scan is still controversial. Methods: We retrospectively analyzed 42 patients with primary gastric lymphoma who underwent PET/CT scans; 32 patients with diffuse large B-cell lymphoma (DLBCL) and 10 patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) were analyzed. The PET/CT scans were compared with clinicopathologic features and the results of CT and endoscopy. After corresponding treatment, response was evaluated by conventional CT scans or PET/CT scans and endoscopy with biopsy Results: Nine patients were up-staged based on the results of their PET/CT scan compared to CT (7 DLBCL, 2 MALT lymphomas) while six patients were down-staged by the PET/CT scan. The high SUVmax group, defined as SUVmax ≥ median value, was significantly associated with an advanced Lugano stage (P < 0.001). Three patients with DLBCL, who showed an initially high SUVmax, died of disease progression. Although not statistically significant, there was a tendency of inferior outcome in the group with high SUVmax. Among 24 patients for whom follow-up PET/CT scan with endoscopy was performed, 11 patients with ulcerative or mucosal lesions showed residual FDG uptake. All of these gastric lesions were grossly and pathologically benign lesions without evidence of lymphoma cells. Conclusions: PET/CT scan can help staging patients with primary gastric lymphoma, and the maximum SUV has possibility to have prognostic value. However, the residual FDG uptake observed during follow-up should be interpreted cautiously in association with the results of endoscopy and multiple gastric biopsies. No significant financial relationships to disclose.
3
Shah, S. A., V. Rangarajan, N. C. Purandare, A. R. Sharma, A. C. Arora, and D. S. Parasar. "A pilot study to compare 8 - FDG and F18 PET/CT study in delineating metastases in suspected skeletal disease." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e22052-e22052. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e22052.
Анотація:
e22052 Title: A pilot study to compare the 18 - FDG and F18 PET/CT study in delineating metastases in suspected skeletal disease. Background: Flourodeoxy glucose (FDG), positron emission tomography/computed tomography (PET/CT) scans have been used to identify metastatic disease including skeletal lesions. But the advent of Flourine -18 (F - 18), has necessitated a need to identify its accuracy over FDG scans. Aim: To evaluate and compare FDG PET/CT and F18 PET/CT studies in locating skeletal metastases in patients with suspected disease. Methods: A pilot study was carried out on 27 patients who were referred for a FDG PET/CT study for suspected skeletal disease. A whole body (skull to ankle) FDG PET/CT study followed by a F18 PET/CT bone scan within a period of 1 week was performed. A total of 150 lesions with increased tracer concentration on FDG and F18 scan were analyzed and the characteristics of the lesion on corresponding CT images were noted. Results: Of the 150 lesions noted, 49 were seen in both FDG and F18 scans. 11 were sclerotic,16 lytic, 17 mixed while CT was normal in 5 lesion. 95 of the 101 mismatched lesions were seen on F18 scan alone & were not appreciated on the FDG scan. 40% were sclerotic, 12% mixed and 11.5% were lytic. Degenerative changes comprised 12% lesions. Only 6 mismatched lesions were seen on FDG and not appreciated on F18 study.They showed no morphological abnormality on CT. 9 patients with a negative FDG scan showed lesions ranging from solitary to 16 on F18 scan, while 5 patients who had a single metastasis on FDG showed more than 6 lesions on a F18 scan. Conclusions: A F18 PET/CT study detects more skeletal lesions than FDG PET and can thus has a potential to impact patient management . Sclerotic lesions missed on FDG scans seem to be better picked on F18 scans. This pilot study provides the feasibility of a prospective study in a larger patient population to validate the impact of F18 scan in identifying skeletal metastases in various malignancies with a predisposition to bone spread. No significant financial relationships to disclose.
4
Murphy, Philip, Siobhan Glavey, Oscar Breathnach, Philip W. Murphy, Liam Grogan, Patrick Morris, and John Quinn. "Non Double-Hit Diffuse Large B Cell Lymphoma Treated with R-CHOP Has Excellent Overall Survival If Interim Scan Shows Partial or Complete Response." Blood 136, Supplement 1 (November 5, 2020): 10. http://dx.doi.org/10.1182/blood-2020-138402.
Анотація:
R-CHOP chemoimmunotherapy is first line therapy for diffuse large B cell non Hodgkin lymphoma (DLBCL), although R-CHOP may be suboptimal treatment for some subtypes of DLBCL, in particular double-hit (DH) or triple-hit (TH) lymphoma. For assessment of response to chemoimmunotherapy, it has been proposed that PET-CT scan may be superior to CT scan and, in particular, demonstration of metabolic complete response (CR) by PET-CT scan at end of treatment (EOT) may be an important indicator of long term survival. However, the usefulness of follow up scans in asymptomatic patients remains debatable. We wished to assess the role of an interim CT or PET-CT scan (after 3-4 courses of chemoimmunotherapy) in predicting overall survival in patients at our centre with stage II- IV DLCBCL (Lugano Modification of Ann Arbor Classification) who received chemoimmunotherapy with curative intent. We also recorded results of scans at EOT and any further follow up scans. Between 1/7/15 and 1/7/19, 43 consecutive patients receiving R-CHOP had an interim CT or PET-CT scan. 3 of 4 patients with DH lymphoma by FISH testing changed to dose adjusted R-EPOCH after one course of R-CHOP. 39 patients had no evidence of DH, with 37 showing either partial response (PR) (N = 11) or CR (N=26) on interim CT or PET-CT scan. Of these 37 cases, one patient died of neutropenic sepsis, whilst 36 remain alive with 35 in complete remission. 30 of these 37 patients had CT scan and/or PET-CT scan at EOT: 27 were in CR, 2 were in stable PR and 1 patient (in CR on interim PET -CT scan) showed relapse on PET-CT scan. 16 patients in CR at EOT had 55 follow up surveillance scans (median 2, range 1-8) -two further relapses were detected on PET-CT scan, both 4 months after EOT. Two of the relapsed cases are in CR following further chemoimmunotherapy and allogeneic stem cell transplant whilst the other relapsed case is currently responding to further chemoimmunotherapy. 2 patients without evidence of DH showed disease progression on interim scan and were refractory to further chemotherapy, dying within 3 months and 18 months of diagnosis. All 4 patients with DH lymphoma had PR or CR at interim scan but relapsed within 5 to 8 months after diagnosis and proved chemotherapy refractory with death in 3. One patient with DH lymphoma remains in CR following local radiation and maintenance therapy with rituximab, lenalidomide and metformin. In our experience, patients with DLBCL, without DH or TH, who have evidence of response to R-CHOP at interim scan have an excellent prognosis. In this patient cohort, 85 EOT and follow up scans detected 3 relapses, suggesting that the detection rate of follow up scans in asymptomatic patients in this good prognosis group is low and of questionable usefulness. The 3 relapsed patients were readily salvageable by further chemoimmunotherapy with or without allogeneic stem cell transplant. In contrast, patients with DH lymphoma or evidence of disease progression on interim scan have very poor prognosis and urgently require alternative therapy approaches. Disclosures No relevant conflicts of interest to declare.
5
Parsons, Susan K., Kristina S. Yu, Nicholas Liu, Supriya Kumar, Michelle A. Fanale, Katie Holmes, Carlos Flores, Andy Surinach, Darcy R. Flora, and Andrew M. Evens. "Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens." Blood 138, Supplement 1 (November 5, 2021): 1390. http://dx.doi.org/10.1182/blood-2021-151143.
Анотація:
Abstract Background Current NCCN guidelines recommend 1 of 3 first-line (1L) regimens for stage III or IV classical Hodgkin lymphoma (cHL): ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), A+AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine), or escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone); preferred regimens vary by region (e.g., North America vs Europe). The NCCN recommends positron emission tomography/computerized tomography (PET/CT) imaging after cycle 2 (interim PET2) to guide ABVD escalation or de-escalation. We surveyed physicians on their cHL treatment decision-making process and how PET/CT scan access, reimbursement, and comprehension influence their choices as part of CONNECT, the first real-world survey of physicians, patients, and caregivers in cHL. Methods Medical oncologists, hematologist/oncologists, or hematologists who treat cHL were invited to participate in an Institutional Review Board-approved, 30-minute online anonymous survey. Eligible participants had ≥2 years of practice experience in the United States (US) and treated ≥1 adult (aged ≥18 years) with stage III or IV cHL and ≥1 adult with cHL in the 1L setting within the prior 12 months. Surveys were completed from October 19, 2020-November 16, 2020. Results Of 301 participating physicians, 80% were hematologist/oncologists with a median practice duration of 15 years; 62% practiced in community and 38% in academic settings. Participants were located in the US (South, 34%; Northeast, 26%; West, 21%; Midwest, 20%) and spent 90% of their professional time in direct patient care. In the preceding 12 months, participants treated a median (interquartile range) of 16 (7-40) patients with active cHL (stage III [median], 4; stage IV, 5) and 15 (8-40) cHL survivors. When treating cHL, 88% of participants reported giving NCCN guidelines somewhat/significant consideration. Overall, 94% of participants (n=284) reported using a PET/CT combined scan to diagnose/stage cHL, in line with current guideline recommendations. Of these participants, 97% reported typically getting an interim PET/CT scan for stage III or IV cHL with 65% typically getting the scan after cycle 2 (Figure A). Participants reported both escalating and de-escalating treatment based on interim PET/CT results (Figure B) with 61% making decisions after cycle 2. Of participants using a PET/CT scan, 42% reported receiving both a Deauville score and a standardized uptake value (SUV; Figure C) with 62% of participants noting that the Deauville score was the primary system used for reviewing PET/CT results (Figure D). However, 19% of participants reported challenges interpreting PET/CT results. Among participants using a Deauville score (n=209), consensus was limited on what defined a positive scan (≥3, 44%; ≥4, 37%). Challenges obtaining PET/CT scans were reported by 16% of participants using PET/CT scans. However, despite not reporting challenges 55% of participants on average were unable to obtain a PET/CT scan 20% of the time. Of participants using PET/CT scans, 86% reported typically receiving results within 2 business days and 14% within 3-5 business days. Twenty-one percent of participants reported that delays in PET/CT results affected their ability to use a PET-adaptive approach. Forty-nine percent of those using PET/CT scans reported increased difficulty in PET/CT access for stage III or IV cHL due to lack of insurance coverage. In absence of a PET/CT scan, 36% of participants reported using an interim biopsy and 63% an interim CT scan to inform treatment choices. Among all participants, 36% reported increased difficulty in getting patients with cHL access to PET/CT scans due to COVID-19. Conclusions Although participants consider NCCN guidelines when treating cHL, interim PET scans are not universally obtained after cycle 2 for stage III or IV cHL, with 65% of participants who use PET/CT scans obtaining an interim PET scan after cycle 2 for stage III or IV cHL. When PET/CT scans are obtained, Deauville scores are commonly provided; however, there is variability in what is termed a positive or negative Deauville score. Challenges in obtaining PET/CT scans, with increased difficulty during COVID-19, were reported. Also, there are other barriers, such as lack of insurance, that may prohibit the optimal adherence to guidelines on interim PET/CT utilization. Figure 1 Figure 1. Disclosures Parsons: SeaGen: Consultancy. Yu: Seagen, Inc: Current Employment, Current equity holder in publicly-traded company. Liu: Seagen, Inc: Current Employment, Current equity holder in publicly-traded company. Kumar: Seagen, Inc: Consultancy. Fanale: Seagen, Inc: Current Employment, Current equity holder in publicly-traded company. Flora: Seagen, Inc: Research Funding.
6
Short, Susan C., Russell Frood, David Broadbent, Sharon Fernandez, Garry McDermott, Bashar Al-Qaisieh, David Buckley, Stuart Currie, Louise Murray, and Andrew Scarsbrook. "NIMG-16. FEASIBLITY OF FLUORINE-18 FLUCICLOVINE PET-CT AND MRI FOR MONITORING OF CHEMO-RADIATION IN GLIOBLASTOMA: INITIAL RESULTS FROM A PILOT STUDY." Neuro-Oncology 21, Supplement_6 (November 2019): vi164—vi165. http://dx.doi.org/10.1093/neuonc/noz175.688.
Анотація:
Abstract BACKGROUND Glioblastoma has a poor prognosis despite treatment with surgery and chemo-radiotherapy (CRT). Monitoring early response to CRT is challenging and conventional imaging is sub-optimal for stratifying poorly responding patients for novel agents. Also, imaging is not routinely performed during CRT and consequently, personalised treatment through individualised radiation dose adaption is not possible. AIMS: To evalutate the feasibility of Fluorine-18 Fluciclovine PET-CT for early response assessment during and post-treatment in patients with glioblastoma undergoing standard-of-care CRT. METHODS Patients with confirmed glioblastoma and macroscopic residual tumour post-surgery were consented for PET-CT and MRI prior to CRT (scan 1), after completing 2 weeks (10 fractions) of CRT (scan 2) and 6 weeks after completing treatment (scan 3). For each scan, patients were immobilised in a radiotherapy treatment mask. PET-CT and MRI scans were performed at each timepoint within a few days of each other. Patients were treated and followed up according to local guidelines. RESULTS 6 patients were recruited to the study between June 2018 and May 2019. All patients tolerated the additional imaging without problems. 2 patients were unable to attend their post-treatment PET-CT scan due to clinical deterioration. Fluciclovine PET-CT highlighted potentially active disease beyond the surgical cavity pre-radiotherapy (scan 1) in 3 patients. In 4/6, PET signal persisted after 2 weeks of radiotherapy with stable MRI appearances (scan 2). Frank disease progression was seen in 1 patient on both MRI and PET-CT mid-treatment. 3/4 patients with persistent activity at scan 2, showed disease progression post-treatment on both PET-CT and MRI (scan 3). Another had progressive changes on MRI but stable PET-CT appearances possibly representing pseudoprogression. CONCLUSION These preliminary results suggest that Fluciclovine PET-CT could help in monitoring treatment and further work to assess the ability to guide individualised treatment planning in glioblastoma is warranted.
7
Volkow, Nora D., and Laurence Tancredi. "Neural Substrates of Violent Behaviour a Preliminary Study with Positron Emission Tomography." British Journal of Psychiatry 151, no. 5 (November 1987): 668–73. http://dx.doi.org/10.1192/bjp.151.5.668.
Анотація:
Brain function was evaluated in four psychiatric patients with a history of repetitive purposeless violent behaviour, using EEG, CT scan, and positron emission tomography (PET). Three patients showed spiking activity in left temporal regions, and two showed CT scan abnormalities characterised by generalised cortical atrophy. The PET scans for the four cases showed evidence of blood flow and metabolic abnormalities in the left temporal lobe. Two patients also had derangement in the frontal cortex. The patients showing the largest defects with the PET scans were those whose CT scans were reported as normal. This paper shows the utility of PET in investigating possible brain derangements that could lead to violent behaviour.
8
Durani, Urshila, Dennis Asante, Thorvardur Halfdanarson, Herbert C. Heien, Lindsey Sangaralingham, Carrie A. Thompson, Prema Peethambaram, Fernando J. Quevedo, and Ronald S. Go. "Use of Imaging During Staging and Surveillance of Localized Colon Cancer in a Large Insured Population." Journal of the National Comprehensive Cancer Network 17, no. 11 (November 2019): 1355–61. http://dx.doi.org/10.6004/jnccn.2019.7315.
Анотація:
Background: Adherence to surveillance guidelines in resected colon cancer has significant implications for patient morbidity, cost of care, and healthcare utilization. This study measured the underuse and overuse of imaging for staging and surveillance in stage I–II colon cancer. Methods: The OptumLabs database was queried for administrative claims data on adult patients with stage I–II colon cancer who underwent surgery alone in 2008 through 2016. Use of PET and CT imaging was evaluated during both initial staging (n=6,921) and surveillance for patients with at least 1 year of follow-up (n=5,466). “High use” was defined as >2 CT abdominal/pelvic (CT A/P) or PET scans per year during surveillance. Results: Overall, 27% of patients with stage I–II colon cancer did not have a staging CT A/P or PET scan and 95% did not have a CT chest scan. However, rates of staging CT A/P and CT chest scans increased from 62.0% (2008) to 74.8% (2016) and from 2.3% (2008) to 7.1% (2016), respectively. Staging PET use was overall very low (5.2%). During surveillance, approximately 30% of patients received a CT A/P or PET and 5% received a CT chest scan within the first year after surgery. Of patients who had surveillance CT A/P or PET scans, the proportion receiving >2 scans within the first year (high use) declined from 32.4% (2008) to 9.6% (2016) (P = .01). Conclusions: Although PET use remains appropriately low, many patients with stage I–II colon cancer do not receive appropriate staging and surveillance CT chest scans. Among those who do receive these scans during surveillance, high use has declined significantly over time.
9
Kodzo-Grey Venyo, Anthony. "The Role of Positron Emission Tomography - Computed Tomography (PET - CT) Scan in the Assessment and Management of Carcinoma of the Prostate Gland: A Review and Update." Clinical Research and Clinical Trials 4, no. 2 (August 24, 2021): 01–17. http://dx.doi.org/10.31579/2693-4779/054.
Анотація:
Background: PET CT Scan has been used on numerous occasions in the assessment and management of various malignancies but it is only occasionally used in the assessment management of carcinoma of the prostate gland globally. There is the need to establish whether or not PET/CT scan is a useful imaging technique which should be used more often in the investigation of biochemical failure following treatment of carcinoma of prostate gland with curative intent Aim: To investigate the suggestion that PET/CT scan would be a useful and reliable imaging option for the investigation of biochemical recurrence resulting following the treatment of prostate cancer with curative intent by reviewing the literature relating to the use of PET / CT scan in carcinoma of the prostate gland. Method: Various internet data bases were searched including: Google, Google Scholar, Yahoo, and PUBMED. The search words that were used included: PET/CT Scan in carcinoma of the prostate, PET/CT scan in prostate cancer, PET/CT scan and prostate cancer, PET/CT scan and carcinoma of the prostate. Results: Fifty two manuscripts that have been published relating to the use of a form of PET/CT scan in relationship to investigation of carcinoma of the prostate gland were utilized to write the article. One of the articles published in Dutch was a review article. Another paper reported the use of PET CT scan in the diagnosis of Hurtle tumour (a benign tumour) in association with carcinoma of the prostate gland. The remaining manuscripts contained case reports and studies regarding the use of various types of PET/CT scan in the investigation of biochemical failure as well as in the treatment and follow-up of some cases of metastasis. On the whole almost all of the papers had confirmed the high sensitivity and high specificity of PET/CT scan in detecting localized and distant metastatic lesions in the scenario of slight elevations of serum PSA. There have been reports of PET/CT scan being able to detect localized and distant metastasis when conventional computed tomography scan and isotope bone scan failed to detect metastases. In one case when the serum PSA level was high isotope bone scan and CT scan failed to detect bone metastases but PET/CT scan detected bone metastases. Conclusions: PET/CT Scan is a very useful imaging modality that detects localized and distant metastases in biochemical recurrence of prostate cancer and this modality of imaging should be used more often from now onwards. CT scan would usually detect nodes/lesions that measure 1 cm or larger but PET/CT scan would detect smaller sized lesions at slightly raised levels of serum PSA. The detection of small localized metastasis at a slightly elevated serum PSA values would make it easier for the undertaking of a second-line treatment of curative intent in the form of salvage lymphadenectomy or salvage radiotherapy targeted at the lesion. Perhaps PET/CT scan should be the first-line imaging modality which should be used in investigating biochemical recurrence and this should be done when the serum PSA is slightly elevated.
10
Ho, Maria Yi, Tarnjit Parhar, Don Wilson, Winson Y. Cheung, and Howard John Lim. "A population-based study of the effect of FDG PET/CT in the management of liver-limited colorectal adenocarcinoma (CRC) metastases." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 3610. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.3610.
Анотація:
3610 Background: PET/CT scans are publically funded in British Columbia for staging in liver limited metastatic CRC. However, past studies have been equivocal about the utility of PET/CT as some report as high as a 20-30% change in management while others report <10% change in management. Our primary objective was to assess the effect of the addition of PET/CT to CT scanning for the management of liver limited colorectal cancer. Methods: Patients who underwent PET/CT scan for de novo liver limited metastatic disease from 2005-2011 in the province of British Columbia were identified using the PET/CT database. Patients recently completed or currently on chemotherapy were excluded. We determined the concordance rates between CT and PET/CT scans with respect to the extra-hepatic disease, the number of lesions in the liver and the location of liver lesions. Results: 349 patients were identified. The most common indications for PET/CT scans after an initial CT scan were: detection of extrahepatic disease (77%), confirmation of the malignant nature of the liver lesions (8%) and the extent of extrahepatic disease (15%). PET/CT and CT were discordant in 39% of cases for the extent of metastatic disease. PET/CT revealed extrahepatic disease in 27% of the cases for which CT only detected liver limited disease. In contrast, 13% of patients were downstaged when CT liver lesions were demonstrated not to be FDG avid. Concordance of PET/CT and CT scans on the number and location of liver lesions was 52% and 85%, respectively. PET/CT revealed additional number of liver lesions and multilobar disease in 26% and 12% of cases, respectively. Furthermore, the median time between PET/CT and CT were 64.3 days and 64.1 days for concordant and discordant cases (p=0.88). Conclusions: PET/CT scans provided additional information compared to CT scans which could have implications for surgical management. Our study supports the utility and public funding of PET/CT in addition to CT in patients with potentially surgically curable metastatic CRC involving the liver.
Дисертації з теми "PET/CT Scan":
1
Huang, Bingsheng, and 黃炳升. "Radiation dose and cancer risk of cardiac CT scan and PET-CT scan." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2009. http://hub.hku.hk/bib/B41757993.
2
Huang, Bingsheng. "Radiation dose and cancer risk of cardiac CT scan and PET-CT scan." Click to view the E-thesis via HKUTO, 2009. http://sunzi.lib.hku.hk/hkuto/record/B41757993.
3
Dragosavac, Sanja 1977. "PET/CT com FDG-18 F em pacientes com suspeita de recidiva de carcinoma de ovário." [s.n.], 2011. http://repositorio.unicamp.br/jspui/handle/REPOSIP/309553.
Анотація:
Orientadores: Gustavo Antonio de Souza, Sophie Françoise Mauricette DerchainDissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas
Made available in DSpace on 2018-08-18T16:26:27Z (GMT). No. of bitstreams: 1 Dragosavac_Sanja_M.pdf: 1871037 bytes, checksum: 792409d11e54caa65d34f4ecbee851f0 (MD5) Previous issue date: 2011
Resumo: O exame PET/CT com FDG-18F é um método de diagnóstico por imagem, útil em oncologia. O câncer de ovário é o câncer ginecológico de maior letalidade, sendo a terceira neoplasia mais freqüente do trato genital feminino no Brasil. O objetivo deste estudo foi avaliar o PET/CT com FDG-18F em pacientes com suspeita de recidiva de carcinoma de ovário e descrever a distribuição das lesões encontradas. Sujeitos e Métodos: Foram incluídas neste estudo retrospectivo 45 mulheres com suspeita de recidiva de câncer de ovário. As pacientes foram encaminhadas para clínica PET/CT Campinas de novembro 2006 até novembro de 2010, por aumento do CA-125, sintomas clínicos e/ou alterações na ultrassonografia (US), tomografia (TC) ou ressonância (RM). Para a confirmação da recidiva, 15 pacientes foram submetidas à cirurgia e 30 foram acompanhadas por um período mínimo de seis meses. Resultados: Quarenta e duas pacientes foram diagnosticadas com recidiva e três não apresentaram evidência de doença durante o período de acompanhamento. O CA-125 estava aumentado em 34 pacientes, 14 apresentavam sintomas clínicos e 23 tinham alterações em US, TC ou RM. Trinta e oito pacientes apresentaram o exame PET/CT positivo, todas com recidiva confirmada. Três pacientes apresentaram achados inconclusivos na PET/CT, todas com doença. Quatro exames de PET/CT eram negativos, sendo que uma paciente teve recidiva confirmada e as demais permaneceram sem evidências de doença durante o acompanhamento. Onze pacientes com CA-125 elevado apresentavam resultados de US, TC ou RM normais. Todas tiveram doença confirmada, sendo que a PET/CT detectou recidiva em nove e foi inconclusiva em duas. Entre as onze pacientes com CA- 125 normal, foram detectadas metástases na PET/CT em oito. As metástases mais freqüentes foram diagnosticadas em linfonodos, sendo localizados na região pélvica e abdominal em 30 pacientes, na região torácica em 16 e em sete pacientes, na região cervical. Implantes pélvicos e abdominais foram detectados em 27 pacientes. Outros locais de metástases foram fígado (n=7), baço (n=2), pleura (n=2), pulmão (n=2) e osso (n=2). O exame PET/CT detectou lesões não suspeitas em 20 das 45 pacientes (44,4%). A PET/CT detectou um novo tumor primário de tireoide numa paciente sem recidiva de carcinoma de ovário. Conclusão: O exame PET/CT foi útil para avaliação da extensão da recidiva de carcinoma de ovário. A recidiva acometeu mais freqüentemente os linfonodos, sendo a maioria localizada na região pélvica e abdominal. Metástases em linfonodos torácicos foram um achado freqüente nesta população estudada
Abstract: 18F-FDG PET/CT is a diagnostic method useful in oncology. Ovarian cancer is the third most frequent cancer of the female genital tract in Brazil, however, it has the highest mortality of all gynecological cancers. The aim of this study was to evaluate the use of 18F-FDG PET/CT in patients with suspected ovarian cancer recurrence and describe the distribution of metastasis. Methods: Fortyfive female patients with suspicion of ovarian cancer recurrence were included in this retrospective study. They were referred to PET/CT Campinas clinic from November 2006 to November 2010, because of elevated CA-125, clinical suspicion of ovarian cancer recurrence, or alterations detected on ultrasound (US), computed tomography (CT) or magnetic resonance imaging (MRI). PET/CT results were compared with histologic findings (n=15) or clinical followup for at least six months (n=30). Results: Forty-two patients were confirmed with ovarian cancer recurrence. Three patients remained free of disease during clinical follow-up. CA-125 was elevated in a total of 34 patients, 14 patients had clinical symptoms of disease and 23 presented with alterations on US, CT and MRI. Thirty eight patients had positive PET/CT scan, all with confirmed disease. Three patients had equivocal PET/CT findings and in all three, recurrence was confirmed. Four patients had negative PET/CT scan: one with confirmed recurrence and three free from disease during follow-up. Nine out of 11 patients with elevated CA-125 and normal conventional imaging had positive PET/CT scan and two had equivocal findings. There were eleven patients with normal CA-125 levels, eight presented with positive PET/CT scan. Lymph nodes were the most frequent site of relapse of disease, most being in the pelvic/abdominal region (n=30) and others in thoracic (n=16) or cervical region (n=7). Peritoneal implants were found in 27 patients. Distant sites of metastasis included liver (n=6), spleen (n=2), pleura (n=2), lung (n=2) and bone (n=2). PET/CT detected unsuspected lesions in 20/45 patients (44.4%). One patient with PET/CT negative for ovarian cancer recurrence was diagnosed with primary papillary carcinoma of the thyroid. Conclusion: 18F-FDG PET/CT was a useful tool for evaluation of the extension of ovarian cancer recurrence. In the current series, lymph nodes were the most frequent site of relapse of disease, with supradiaphragmatic lymph node metastasis in large number of cases
Mestrado
Oncologia Ginecológica e Mamária
Mestre em Ciências da Saúde
4
Ormeño, Lara Alexandra Sayuri. "Valor de la eficiencia de los cristales en relación a la cuantificación del SUV en PET-CT PET SCAN Perú - CAMN agosto 2017 - noviembre 2018." Bachelor's thesis, Universidad Nacional Mayor de San Marcos, 2019. https://hdl.handle.net/20.500.12672/10682.
Анотація:
Establece la relación del valor de la eficiencia de los cristales con la cuantificación del SUV. El estudio es de tipo observacional, cuantitativo, longitudinal, prospectivo y de nivel relacional. Se realizaron 50 controles de calidad obteniendo el ECF diario, así como el SUVmáx., temperatura ambiental, temperatura del gantry y humedad relativa en la mañana, medio día y tarde diariamente. Proceso realizado en PET SCAN PERÚ – CAMN durante el año 2018. Los valores del Factor de la Eficiencia de los Cristales (ECF) están entre 2,775 y 2,803. El Valor de Captación Estándar (SUVmáx.) varía entre 0,9921 y 1,0869. La temperatura ambiental se localiza en el rango de 17,67 °C y 21, 07 °C. Los valores de la temperatura del gantry se ubican entre 34,67 y 36,67. Mientras que la humedad relativa está entre 39,33% y 52%. Se concluye que existe correlación inversamente proporcional entre el Factor de la Eficiencia de los Cristales (ECF) y el Valor de Captación Estándar (SUVmáx.), por lo cual, se sugiere continuar con los controles de calidad diario. Además, la temperatura influye indirectamente al SUV máx.Tesis
5
See, Shiu-king Eric, and 施兆景. "The use of neural network analysis of PET-CT brain scan regional ¹⁸F-FDG metabolism in diagnosis and prognosis of dementia subjects." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hub.hku.hk/bib/B50712780.
Анотація:
The elderly population (those aged 65 years or older) in Hong Kong is expected to increase from approximately 13% in 2009 to 28% by 2039. With this rapid growth of elders, it raises attention to prevent and treat chronic diseases of aging. Dementia is particularly concerned because the short term memory loss and other cognitive malfunctions lead to a loss of independent function that has a extensive impact on individuals, families, health and social welfare systems. Currently over 70,000 people endure dementia in Hong Kong and expect quadruple rises by 2036. In order to cope with these diseases, accurate diagnosis is very useful, particular at early stage when treatment outcomes are most effective.
Numerous studies have found that AD and other dementias could alter brain metabolism significantly. AD patients usually present the posterior cingulated and parietotemporal cortices hypometabolism and spread into the frontal lobes in advanced disease. In contrast, FTD patients show manifestly hypometabolism in the frontal and anterior temporal cortices, while DLB patients present hypometabolism in the posterior brain comprising primarily the parietoocipital regions. Theoretically, 18F-FDG PET scan can help in the early diagnosis of AD and other dementias by highlighting these decreased FDG uptake cortex regions before MRI or CT scans can detect any structural damage.
This is a retrospective chart review study. Patients who had received FDG brain PET-CT scan previously had their regional brain metabolism quantitated using a software call Cortex-ID and clinical laboratory tests. The study is
* To develop a Neural Network (NN) that can diagnose the various types of dementia using Brain PET-CT scan, testing accuracy of NN versus an expert and,
* To see if the NN can correlate with the clinical severity of the disease as reflected by MMSE score.
Finally, three neural networks have been designed and they all fulfill all the required specifications.published_or_final_version
Diagnostic Radiology
Master
Master of Medical Sciences
6
Snyman, Leon Cornelius. "Efficacy of the sentinel lymph node biopsy algorithm and PET/CT scan in assessing regional lymph node status in women with early stage endometrial and cervical cancer in a South African population." Thesis, University of Pretoria, 2017. http://hdl.handle.net/2263/64296.
Анотація:
Abstract
Introduction
Knowledge about the oncologic status of pelvic lymph nodes forms an essential and integral part in the management of women with uterine cancer. Lymph node status is part of endometrial cancer staging and plays an important role in primary treatment and adjuvant treatment planning and prognosis in women with cervical cancer. Current practice in the management of uterine cancers involves systematic full pelvic lymphadenectomy, mainly to determine the oncological status of the nodes, as there is no high-quality evidence suggesting a therapeutic effect attributable to lymphadenectomy.
Imaging in the form of computed tomography (CT) scans and magnetic resonance (MRI) scan is not accurate to determine pelvic lymph node status in women with uterine cancer. Functional scans such as 18Fluoro-deoxy-glucose positron emission/computed tomography (FDG-PET/CT) scan might provide better access in this setting.
Sentinel lymph node biopsy (SLNB) procedures, specifically the SLNB algorithm, have been proposed as a safe and accurate alternative procedure to full systematic lymphadenectomy in women with uterine cancers. It has also been proposed as a better alternative than complete omission of lymphadenectomy in women with presumed low risk early stage endometrial cancer. SLNB procedures might also be able to detect higher rates of lymph node metastases with the detection of micro metastases following pathological ultrastaging
The presence or absence of high risk human papilloma virus (hrHPV) DNA in sentinel lymph nodes of women with cervical cancer has also been suggested to be a useful adjunct to frozen section examination (FSE) in assisting with determination of the status of the non-sentinel nodes. Some data suggest the combination of negative FSE and absence of hrHPV accurately predict the absence of metastases.
South African women have high prevalence of human immunodeficiency virus infection, tuberculosis (TB) and pelvic inflammatory disease (PID). All these infections involve the lymphatic system. Data on SLNB procedures are form well-developed countries with different disease burdens and socioeconomic profiles, and there is no data from women living in low-resource settings.
Aims
This study aimed to determine the efficacy of and performance of FDG-PET/CT scan and SLNB and SLNB algorithm in accurately predicting the regional lymph node status of the pelvis in women with early stage cervical cancer and presumed early stage endometrial cancer. It also aimed to investigate the usefulness of HPV DNA testing of sentinel nodes in women with cervical cancer.
Population and setting
This was a prospective observational study performed in the Gynaecologic Oncology Unit at the Kalafong Provincial Tertiary Hospital and Steve Biko Academic Hospital.
Patients aged 18 years and older, with operable stages cervical cancer and presumed early stage endometrial cancer willing and able to provide informed consent were eligible for inclusion.
Materials and methods
Sentinel node mapping was done using methylene blue (MB) and indocyanine green (ICG) injected into the cervix after induction of anaesthesia at the time of primary surgery. 99Technetium nanocolloid (99Tc) was administered one day pre-operatively followed by lymphoscintigram. FDG-PET/CT scans were performed prior to surgery.
Following mapping and removal, FSE, HPV DNA typing, haematoxylin and eosin (H&E) examination with ultrastaging on H&E negative specimens were performed on the SLNs. All patients underwent systematic full pelvic lymphadenectomy and appropriate cancer surgery.
Results
One hundred patients were prospectively recruited to the study and results of 94 patients were available for analysis. SNL detection rate of the whole group was 60.6% with bilateral detection 29.2%. Twenty-four patients (25.5%) had pelvic metastases.
Sixty-five percent of women with cervical cancer in this study were HIV positive, and the SLN detection rate in this group was 65% with bilateral detection rate of 30%. The detection rate was significantly higher in women without nodal metastases, those with stage IA2 – IB2 disease, with tumour less than 2 cm and women with BMI less than 25 kg/m2. HIV status, history of TB, PID and the presence of adhesions did not influence the SLN detection rate. The sentinel lymph node biopsy algorithm has a sensitivity of 100%, NPV of 100% and a false negative rate of 0% in this study. The SLNB procedure identified two women with only micro metastases (15.4%). These women would not have been identified with systematic lymphadenectomy and H&E examination.
Indocyanine green and the combination of methylene blue and 99Technetium nanocolloid had significantly better sentinel node detection rates compared to methylene blue alone
FDG-PET/CT scan was performed in 28 women. The sensitivity, specificity, positive and negative predictive values of FDG-PET/CT scans to accurately predict nodal status, were 66.67%, 82%, 30.77% and 95.38% respectively. The false negative rate of FDG-PET/CT scans was 33.3%.
The sensitivity, specificity, PPV and NPV for FSE in this cohort was 66.67%, 100%, 100% and 96.05% respectively. The FNR for FSE was 23.1%.
Thirty-two patients with cervical cancer had tumour and SLN hrHPV DNA data. The sensitivity, specificity, PPV and NPV of sentinel lymph node HPV DNA to predict metastases was 50%, 69.6%, 30 and 84.2% respectively with a false negative rate of 42.8%.
Conclusions
Although the SLN detection rate was lower compared to the published literature, the SLNB algorithm performed excellently in this group of patients of which the majority were HIV-infected.
The SLNB procedure can be considered as a treatment option in selected cases in the management of women with early stage endometrial and cervical cancer.
PET/CT should not be used as part of the primary diagnosis and staging investigations in women with uterine cancer, and is recommended only in selected cases for initial staging of locally advanced cervical cancer being considered for radical chemoradiation therapy.
In this study, testing for the presence of hrHPV DNA in the sentinel lymph nodes was not useful as a predictor of pelvic lymph node status. The combination of negative FSE and negative hrHPV in the SLNs did not have a reliable negative predictive value for the absence of pelvic nodal metastases.Thesis (PhD)--University of Pretoria, 2017.
Obstetrics and Gynaecology
PhD
Unrestricted
7
Al, Mahdawi Basil Mohamed Nouri. "Senior monitoring by using sensors network and optical metrology." Thesis, Bourgogne Franche-Comté, 2017. http://www.theses.fr/2017UBFCD085.
Анотація:
L’objectif du travail de cette thèse est la contribution au développement de nouvelles techniques dans le domaine dessystèmes de détection sans marqueur pour une utilisation dans trois domaines vitaux de la santé en utilisant des capteursinnovants et peu coûteux. Pour la réalisation de nos objectifs nous avons eu recours principalement à de l’électroniqueembarquées et du traitement du signal en utilisant le capteur Kinect. Des résultats encourageants ont été obtenus et sontprésentés tout au long de cette thèse. Dans la première partie de ce travail, nous présentons un nouveau système desurveillance visuelle sans marqueur en temps réel pour détecter et suivre les personnes âgées et surveiller leurs activitésdans leur environnement intérieur en utilisant un réseau de capteurs Kinect. Le système identifie également l’événementde chute des personnes âgées sous surveillance. Dans la deuxième partie nous utilisons également le capteur Kinectmais cette fois ci pour la détection sans marqueur des mouvements de la tête d’un patient lors d’un examen utilisant LaTomographie par Emission de Positons (CT/PET) du cerveau. Ce travail est basé sur la compensation de la dégradationde l’image TEP due aux mouvements de la tête du patient. Pour nos essais un cobaye dit « fantôme » a été réalisé,les résultats sur le fantôme sont prometteur ce qui a donné lieu à un test sur un vrai patient volontaire. Les résultatsfinaux montrent l’efficacité de ce nouveau système. La troisième partie du travail présente la mise en oeuvre d’un nouveausystème intelligent pour contrôler un fauteuil roulant électrique par des mouvements spéciaux de la tête toujours sansmarqueur. Un algorithme adapté est conçu pour détecter en continu les degrés des mouvements du visage en utilisant lecapteur Kinect. Fautes de fauteuil roulant électrique, le système a été testé sur un véhicule radio commandéThe objective of the work of this thesis is the contribution in developing novel technical methods in the field of marker-lesssensing systems for use in three vital health areas by using new inexpensive sensors. Several scientific areas are involvedin achieving our objective such as; electronics and signal processing by using the Kinect sensor. Encouraging results wereachieved as presented throughout this thesis. In the first part of this work we present a new real-time marker-less visualsurveillance system for detecting and tracking seniors and monitoring their activities in the indoor environment by usingnetwork of Kinect sensors. The system also identifies the fall event with the elderly. In the second part, we present anew approach for a marker-less movement detection system for influential head movements in the brain Positron EmissionTomography imaging (CT/PET) by employing the Kinect sensor. This work addresses the compensation of the PET imagedegradation due to subject’s head movements. A developed particular phantom and volunteer studies were carried out.The experimental results show the effectiveness of this new system. The third part of the work presents the design andimplementation of a new smart system for controlling an electric wheelchair by special mark-less head movements. Anadaptable algorithm is designed to continuously detect the rotation degrees of the face pose using the Kinect sensor inreal-time that are interpreted as controlling signals through a hardware interface for the electric wheelchair actuators
8
Wilson, Colin Michael. "Value of using liver FDG uptake as background activity in standardizing FDG PET/CT studies." Thesis, Boston University, 2011. https://hdl.handle.net/2144/33592.
Анотація:
Thesis (M.A.)--Boston UniversityThe standardized uptake value (SUV) is increasingly being used for diagnosis, staging, and monitoring disease in clinical oncology. Comparing tumor SUV to background SUV is an attractive way to minimize variability and ensure the quality of scans across different institutions. The liver has been identified as a potential source for background normalization, however no studies have compared the liver to other background sites for a variety of cancers. The purpose of this study was to evaluate the use of liver uptake for the standardization of FDG PET/CT imaging. Scans from 145 patients were prospectively reviewed under the supervision of a radiologist with board certification in nuclear medicine (R.M.S. , 3 years of experience). Liver SUV values were correlated to mediastinum SUV values in lung and breast cancer patients, and internal jugular vein (IJV) SUV values in head and neck cancer patients. The independent t-test was used to determine if there was a statistically significant affect of the amount of incubation time or use of intravenous contrast on the SUV. For the lung and breast cancer patients, a strong correlation was observed between the mediastinum SUVmean and liver SUVmean (r = 0.89), whereas for the head and neck cancer patients, a weaker correlation was observed between the IJV SUVmean and the liver SUVmean (r = 0.69). Neither the amount of incubation time nor the use of IV contrast demonstrated a significant affect on the SUV. We conclude that liver SUVmean may be used to standardize FOG PET/CT studies in cancers of the lung, breast and head and neck. However, additional studies in other cancers as well as the affects of age, gender, benign disease and use of chemotherapy are still desired before widespread adoption of this standard.
9
Choudhury, Gourab. "Role of 18F FDG PET/CT as a novel non-invasive biomarker of inflammation in chronic obstructive pulmonary disease." Thesis, University of Edinburgh, 2018. http://hdl.handle.net/1842/33186.
Анотація:
A characteristic feature of Chronic Obstructive Pulmonary Disease (COPD) is an abnormal inflammatory response in the lungs to inhaled particles or gases. The ability to assess and monitor this response in the lungs of COPD patients is important for understanding the pathogenic mechanisms, but also provides a measure of the activity of the disease. Disease activity is more likely to relate to lung inflammation rather than the degree of airflow limitation as measured by the FEV1. Preliminary studies have shown the 18F fluorodeoxyglucose positron emission tomography (18F FDG-PET) signal, as a measure of lung inflammation, is quantifiable in the lungs and is increased in COPD patients compared to controls. However, the methodology requires standardisation and any further enhancement of the methodology would improve its application to assess inflammation in the lungs. I investigated various methods of assessing FDG uptake in the lungs and assessed the reproducibility of these methods, and particularly evaluated whether the data was reproducible or not in the COPD patients (smokers and ex-smokers). This data was then compared with a group of healthy controls to assess the role of dynamic 18F FDG-PET scanning as a surrogate marker of lung inflammation. My data showed a good reproducibility of all methods of assessing FDG lung uptake. However, using conventional Patlak analysis, the uptake was not statistically different between COPD and the control group. Encouraging results in favour of COPD patients were nonetheless shown using compartmental methods of assessing the FDG lung uptake, suggesting the need to correct for the effect of air and blood (tissue fraction effect) when assessing this in a highly vascular organ like the lungs. A prospective study analysis involving a bigger cohort of COPD patients would be desirable to investigate this further.
10
Omarjee, Loukman. "Atteintes Cardiovasculaires du Pseudoxanthome Élastique : Aspects Physiopathologiques et Stratégies Thérapeutiques." Thesis, Angers, 2019. https://dune.univ-angers.fr/documents/dune15886.
Анотація:
L’objectif global de cette thèse était d’étudier, à partir de la cohorte des patients du centre de référence PXE du CHU d’Angers, différente aspects du phénotype cardiovasculaire (CV) du PXE. Ainsi, dans un premier travail, nous avons pu montrer dans l’étude GOCAPXE, que les calcifications ectopiques seraient un processus actif pouvant être détecté par une imagerie moléculaire utilisant un traceur spécifique de l’activité ostéoblastique, le 18-Fluorure de Sodium (18F-NaF); que ce processus était détectable avant même que ces calcifications ne soient visibles par les techniques d’imageries classiques; que ce processus était localisé aux zones habituellement lésées dans le PXE : les plis de flexion et le cou pour la peau et l’artère fémorale superficielle pour le vaisseau. Cette technique mériterait d’être validée dans une étude longitudinale et son rôle en tant biomarqueur diagnostique et de suivi serait ainsi envisageable. Le deuxième travail de cette thèse a été d’étudier les conséquences morphologiques et fonctionnelles d’une augmentation chronique de la pression artérielle chez les patients PXE. Cette question était pertinente car dans la littérature, la question d’une hypertension artérielle (HTA) chez les PXE reste controversée. Nous avons ainsi montré pour la première fois que dans un modèle d’HTA induite par le Deoxycorticostérone (DOCA)-Salt chez la souris Abcc6-/- cette augmentation de la pression artérielle induisait un remodelage CV avec à la fois de la fibrose et des calcifications dystrophiques. Les résultats de cette étude suggèrent la nécessité d’un contrôle optimal de la pression artérielle chez les patients PXE. Le troisième travail de cette thèse a été de caractériser une lésion de la carotide interne détectée avec une fréquence élevée dans la cohorte angevine. Nous avons pu montrer que cette anomalie était une hypoplasie de la carotide interne d’origine probablement congénitale. Chez les patients de la cohorte angevine, cette lésion était associée à des anévrismes intracrâniens mais nous n’avons pas retrouvé d’association avec la survenue d’accident vasculaire cérébral. Ainsi, les résultats de cette étude invitent les praticiens prenant en charge des patients PXE à la rechercher systématiquement dans le bilan vasculaire d’un patient PXE. Si une telle lésion est retrouvée, une imagerie vasculaire intracrânienne devrait être proposée à la recherche d’anévrismes et leur prise en charge discuté en concertation multidisciplinaire. Enfin, le dernier travail a permis de montrer qu’un traitement systémique par le Thiosulfate de Sodium (STS), utilisé dans la calciphylaxie rénale, était efficace sur la régression des calcifications artérielles et cutanées chez une jeune garçon ayant un phénotype CV gravissime résultant de la combinaison délétères de plusieurs gènes pathogènes du spectre PXE Ce traitement mériterait d’être validé dans un essai thérapeutique chez l’humain mais aussi la démonstration de ses mécanismes d’action dans le modèle murin Abcc6-/-. Nous suggérons d’utiliser ce traitement en cas de PXE sévère et rapidement progressif notamment sur le plan vasculaire. Au terme de ce travail de thèse, nous avons montré que le gène ABCC6 était impliqué dans le remodelage vasculaire à la fois au niveau développemental (Hypoplasie Carotidienne) mais aussi acquis (Fibrose, Calcification Cardiaque Dystrophique). Nous avons montré aussi que les calcifications dans le PXE étaient tissus et localisations spécifiques, que ces calcifications étaient actives. Enfin nous avons ouvert la porte à un traitement des formes graves du PXE avec le Thiosulfate de Sodium. Une approche thérapeutique multimodale ciblant plusieurs mécanismes concourant aux calcifications seraient judicieux à évaluer dans les futurs essais cliniquesSince the discovery of the ABCC6 gene in 2000, mutations are at the origin of PseudoxanthomeElastic (PXE), knowledge of genetics, pathophysiology, phenotypic characterizations have has mademajor advances, notably with the Discovery in 2013 of the fundamental role of Pyrophosphateinorganic (PPi) as a deficient anti‐calcifying factor in patients. The overall goal of this thesis was tostudy, from the cohort of patients at the center of PXE reference of the CHU d'Angers, differentaspects of cardiovascular phenotype (CV) of PXE. Thus, in a first work, we were able to show in thestudy GOCAPXE, that ectopic calcifications would be a active process that can be detected by imagingUsing a specific activity tracer Osteoblastic, 18‐sodium fluoride (18F‐NaF); that this process wasdetectable even before these calcifications are not visible by conventional imaging techniques; thatthis process was localized to areas usually injured in the PXE: flexion folds and neck for skin and thesuperficial femoral artery for the vessel. This technique should be validated in a study longitudinaland its role as a diagnostic biomarker In this way, monitoring and monitoring could be considered.The second work of this thesis was to study the morphological consequences and functional of achronic increase in blood pressure in PXE patients. This question was relevant because in theliterature, the question of a high blood pressure (hypertension) in PXE remains controversial. Wehave thus shown for the first time that in a model of HTA induced by the Deoxycorticosterone(DOCA)‐Salt in Abcc6‐/‐ this increase in blood pressure led to a CV remodeling with both fibrosis andcalcifications dystrophic. The results of this study suggest need for optimal control of blood pressurein patients. The third work of this thesis was to characterize a lesion of the internal carotid detectedwith high frequency in the Angevine cohort. We have could show that this abnormality washypoplasia of the Probably congenital internal carotid. In the patients of the angevine cohort, thislesion was associated with intracranial aneurysms but we have not found in association with theoccurrence of vascular accident brain. Thus, the results of this study invite practitioners supportingPXE patients to search for it systematically in the vascular balance of a PXE patient. If such a lesion isfound, vascular imaging Intracranial should be proposed to research Aneurysms and theirmanagement discussed in consultation multidisciplinary. Finally, the latest work has made it possibleto show that systemic treatment with Thiosulphate Sodium (STS), used in renal calciphylaxia, waseffective on the regression of arterial calcifications and skin in a young boy with a phenotype CVGravel resulting from the deleterious combination of several pathogenic genes of the PXE spectrumThis treatment would deserve be validated in a human therapeutic trial but also the demonstrationof its mechanisms of action in the Abcc6‐/‐murin model. We suggest using this treatment for severeand rapidly progressive PXE especially on the vascular plane.At the end of this thesis work, we showed that the ABCC6 gene was involved in vascular remodelingat both at the developmental level (Carotid Hypoplasia) but also acquired (Fibrosis, CardiacCalcification Dystrophic). We also showed that calcifications in PXE were tissues and locationsspecific, that these calcifications were active. Finally we have opened the door to a treatment ofsevere forms of PXE with Sodium Thiosulphate. An approach multimodal therapy targeting multiplemechanisms this would be useful to evaluate in future clinical trials
Книги з теми "PET/CT Scan":
1
Cassels, Alan. What's in a scan?: How well are consumers informed about the benefits and harms related to screening technology (CT and PET scans) in Canada. Ottawa: Canadian Centre for Policy Alternatives, 2009.
2
Cassels, Alan. What's in a scan?: How well are consumers informed about the benefits and harms related to screening technology (CT and PET scans) in Canada. Ottawa: Canadian Centre for Policy Alternatives, 2009.
3
Cassels, Alan. What's in a scan?: How well are consumers informed about the benefits and harms related to screening technology (CT and PET scans) in Canada. Ottawa: Canadian Centre for Policy Alternatives, 2009.
4
Al-Nahhas, Adil, and Imene Zerizer. Nuclear medicine. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0070.
Анотація:
The application of nuclear medicine techniques in the diagnosis and management of rheumatological conditions relies on its ability to detect physiological and pathological changes in vivo, usually at an earlier stage compared to structural changes visualized on conventional imaging. These techniques are based on the in-vivo administration of a gamma-emitting radionuclide whose distribution can be monitored externally using a gamma camera. To guide a radionuclide to the area of interest, it is usually bound to a chemical label to form a 'radiopharmaceutical'. There are hundreds of radiopharmaceuticals in clinical use with different 'homing' mechanisms, such as 99 mTc HDP for bone scan and 99 mTc MAA for lung scan. Comparing pre- and posttherapy scans can aid in monitoring response to treatment. More recently, positron emission tomography combined with simultaneous computed tomography (PET/CT) has been introduced into clinical practice. This technique provides superb spatial resolution and anatomical localization compared to gamma-camera imaging. The most widely used PET radiopharmaceutical, flurodeoxyglucose (18F-FDG), is a fluorinated glucose analogue, which can detect hypermetabolism and has therefore been used in imaging and monitoring response to treatment of a variety of cancers as well as inflammatory conditions such as vasculitis, myopathy, and arthritides. Other PET radiopharmaceuticals targeting inflammation and activated macrophages are becoming available and could open new frontiers in PET imaging in rheumatology. Nuclear medicine procedures can also be used therapeutically. Beta-emitting radiopharmaceuticals, such as yttrium-90, invoke localized tissue damage at the site of injection and can be used in the treatment of synovitis.
5
Wade, Dani. Role of Nuclear Medicine in the Diagnosis of Musculoskeletal Infection: Nuclear Medicine Technology,Musculoskeletal Infection,Bone Scan,PET/CT,Diabetic Foot,Prosthetic Bone Infection,nuclear Medicine. Independently Published, 2021.
6
Kaufmann, Philipp A., and Oliver Gaemperli. Hybrid Cardiac Imaging. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199392094.003.0028.
Анотація:
Assessment of both coronary anatomy and myocardial perfusion are equally important for the appropriate treatment of patients with stable coronary artery disease. Cardiac hybrid imaging allows integration of coronary anatomy and perfusion in one all-in-one image, thereby avoiding mental integration of findings. In selected subgroups of patients, cardiac hybrid imaging has demonstrated superior diagnostic accuracy compared to single modalities. The combination of coronary anatomy and function provides incremental prognostic information and improves risk stratification of patients with suspected or known CAD. Aside from CT coronary angiography, coronary artery calcium score (CACS) scans obtained from native ECG-triggered CT are used for hybrid imaging. They are used either for attenuation correction, or can be combined with radionuclide information to improve CAD detection and risk stratification. A large number of integrated hybrid scanners are commercially available and offer advantages for cardiac hybrid imaging. However, these devices are not mandatory, and hybrid imaging is perfectly feasible from two separate datasets using appropriate image fusion software. Cardiac magnetic resonance has entered the arena of hybrid imaging and several integrated PET/MRI devices are already commercially available. Its advantages include the lack of ionizing radiation and a high spatial resolution, particularly for soft tissue structures. In research, hybrid imaging moves beyond its conventional borders of perfusion imaging to target specific molecular or biological pathways that underlie cardiac disease, a concept known as molecular imaging. The combination of radionuclide imaging with CT or MRI offers attractive features to co-localize biological signals from radiolabeled targeted compounds with microanatomical structures.
Частини книг з теми "PET/CT Scan":
1
Hutchings, Martin, Annika Loft, and Tarec Christoffer El-Galaly. "PET/CT for HL Staging." In PET Scan in Hodgkin Lymphoma, 1–13. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-31797-7_1.
2
Walker, Amanda J., and Stephanie A. Terezakis. "PET/CT in RT Planning." In PET Scan in Hodgkin Lymphoma, 99–115. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-31797-7_5.
3
Ryu, Kyung Nam, Wook Jin, and Ji Seon Park. "Radiography, MRI, CT, Bone Scan, and PET-CT." In Osteonecrosis, 179–95. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-35767-1_23.
4
Papageorgiou, Sotirios G., Vasiliki P. Filippi, and Sofia N. Chatziioannou. "The Role of PET/CT Scan in Primary Gastric Lymphomas." In PET/CT in Lymphomas, 251–56. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-27380-8_14.
5
Goffin, Karolien E., and Wouter Everaerts. "Nuclear Medicine (Bone Scan, Choline and PSMA PET/CT)." In Management of Prostate Cancer, 127–41. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-42769-0_8.
6
Fan, Qiuping, Minggang Su, and Luyi Zhou. "Impact of Scan Duration on PET/CT Maximum Standardized Uptake Value Measurement." In Lecture Notes in Electrical Engineering, 3157–62. Dordrecht: Springer Netherlands, 2013. http://dx.doi.org/10.1007/978-94-007-7618-0_405.
7
Caramella, Davide, Matteo Revelli, and Alessandro Villa. "Radiological Anatomy with CT: What the Nuclear Physician Should Know When Reading a PET/CT Scan." In Nuclear Medicine Textbook, 1241–56. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-95564-3_49.
8
Shi, Kuangyu, Xiaoyin Cheng, Nassir Navab, Stefan Foerster, and Sibylle I. Ziegler. "PET/MRI/VCT: Restoration of Virtual CT from Transmission Scan on PET/MRI Using Joint-Anisotropic Diffusion." In Computational Methods for Molecular Imaging, 25–33. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-18431-9_3.
9
Mazzei, Maria Antonietta, Francesco Gentili, Frida Pittiani, Laura Romanini, and Luca Volterrani. "CT and PET/CT Scans in Gastric Cancer Diagnosis." In Gastric Cancer: the 25-year R-Evolution, 59–65. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-73158-8_7.
10
Shreve, Paul, and Harry Agress. "Performance, Interpretation, and Reporting of PET-CT Scans for Body Oncology Imaging." In Clinical PET-CT in Radiology, 103–16. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-0-387-48902-5_10.
Тези доповідей конференцій з теми "PET/CT Scan":
1
Jabeen Isma, S., N. S. Khakoo, G. Urdaneta, and M. Mirsaeidi. "Characteristic of PET/CT Scan in Sarcoidosis." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4496.
2
Son, Hye-Kyung, Sang Hoon Lee, Sora Nam, and Hee-Joung Kim. "Radiation dose during CT scan with PET/CT clinical protocols." In 2006 IEEE Nuclear Science Symposium Conference Record. IEEE, 2006. http://dx.doi.org/10.1109/nssmic.2006.354353.
3
Sequin, Emily K., Jennifer McFerran-Brock, Joseph West, and Vish Subramaniam. "Eddy Current Detection of Cancer in Surgically Excised Tissue." In ASME 2011 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/sbc2011-53021.
Анотація:
In current clinical practice, a patient usually undergoes a diagnostic computer tomography (CT) scan for evaluation of specific presenting symptoms. The presence of cancer is then confirmed by a diagnostic biopsy or at surgical exploration by histopathologic analysis. Suspicious finding on the diagnostic CT scan may be followed by an 18F FDG (Fluorodeoxyglucose radiolabeled with 18F) positron emission tomography (PET) scan. In a majority of cases, these pre-operative CT and PET scans are used to identify the approximate location of the tumor(s) before surgical intervention. Surgery remains the most effective means of treating solid malignancies despite advances in chemotherapy and radiation therapy [1].
4
Videnovic-Ivanov, Jelica Lj, Violeta M. Mihailovic-Vucinic, Dragana Sobic-Saranovic, Isidora Gvozdic, and Snezana Filipovic-Stepic. "The 18F PET/CT scan in patients with chronic sarcoidosis." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa825.
5
"COMPUTER ASSISTED CANCER DIAGNOSIS SYSTEM USING PET/CT DELAYED SCAN IMAGE." In International Conference on Health Informatics. SciTePress - Science and and Technology Publications, 2011. http://dx.doi.org/10.5220/0003287203990404.
6
Khakoo, N. S., S. Jabeen Isma, M. A. Campos, G. Holt, and M. Mirsaeidi. "PET/CT Scan as a Surrogate for Treatment Outcomes in Sarcoidosis." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4495.
7
Choi, JuWhan, Hyun Seock Shin, Jee Youn Oh, Young Seok Lee, Kyung Hoon Min, Jae Jeong Shim, and Sung Yong Lee. "Abstract B79: PET CT might be better than CT scan when evaluating immune checkpoint inhibitor response." In Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy; November 17-20, 2019; Boston, MA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/2326-6074.tumimm19-b79.
8
RUIZ GARCIA DE ALMEIDA, RICARDO, Celso Dario Ramos, and ANA EMÍLIA TEIXEIRA BRITO. "18F-FDG-PET/CT versus 18F-Fluoride-PET/CT for Detecting Bone Metastases in Patients With Breast Cancer and Equivocal Bone Scan." In XXIV Congresso de Iniciação Científica da UNICAMP - 2016. Campinas - SP, Brazil: Galoa, 2016. http://dx.doi.org/10.19146/pibic-2016-51116.
9
Huang, Sung-Cheng, Hu Ye, Mirwais Wardak, Koon-Pong Wong, Magnus Dahlbom, Weber Shao, Gary W. Small, and Jorge R. Barrio. "A bootstrap method for identifying image regions affected by intra-scan body movement during a PET/CT scan." In 2011 IEEE Nuclear Science Symposium and Medical Imaging Conference (2011 NSS/MIC). IEEE, 2011. http://dx.doi.org/10.1109/nssmic.2011.6152516.
10
Wiebe, D. P., R. L. Myers, S. Atkar-Khattra, D. Wilson, A. McGuire, J. Yee, and S. Lam. "The Utility of PET- CT Scan for Mediastinal Staging of Screen Detected Lung Cancer." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2614.
Звіти організацій з теми "PET/CT Scan":
1
MacFarlane, Andrew. 2021 medical student essay prize winner - A case of grief. Society for Academic Primary Care, July 2021. http://dx.doi.org/10.37361/medstudessay.2021.1.1.
Анотація:
As a student undertaking a Longitudinal Integrated Clerkship (LIC)1 based in a GP practice in a rural community in the North of Scotland, I have been lucky to be given responsibility and my own clinic lists. Every day I conduct consultations that change my practice: the challenge of clinically applying the theory I have studied, controlling a consultation and efficiently exploring a patient's problems, empathising with and empowering them to play a part in their own care2 – and most difficult I feel – dealing with the vast amount of uncertainty that medicine, and particularly primary care, presents to both clinician and patient. I initially consulted with a lady in her 60s who attended with her husband, complaining of severe lower back pain who was very difficult to assess due to her pain level. Her husband was understandably concerned about the degree of pain she was in. After assessment and discussion with one of the GPs, we agreed some pain relief and a physio assessment in the next few days would be a practical plan. The patient had one red flag, some leg weakness and numbness, which was her ‘normal’ on account of her multiple sclerosis. At the physio assessment a few days later, the physio felt things were worse and some urgent bloods were ordered, unfortunately finding raised cancer and inflammatory markers. A CT scan of the lung found widespread cancer, a later CT of the head after some developing some acute confusion found brain metastases, and a week and a half after presenting to me, the patient sadly died in hospital. While that was all impactful enough on me, it was the follow-up appointment with the husband who attended on the last triage slot of the evening two weeks later that I found completely altered my understanding of grief and the mourning of a loved one. The husband had asked to speak to a Andrew MacFarlane Year 3 ScotGEM Medical Student 2 doctor just to talk about what had happened to his wife. The GP decided that it would be better if he came into the practice - strictly he probably should have been consulted with over the phone due to coronavirus restrictions - but he was asked what he would prefer and he opted to come in. I sat in on the consultation, I had been helping with any examinations the triage doctor needed and I recognised that this was the husband of the lady I had seen a few weeks earlier. He came in and sat down, head lowered, hands fiddling with the zip on his jacket, trying to find what to say. The GP sat, turned so that they were opposite each other with no desk between them - I was seated off to the side, an onlooker, but acknowledged by the patient with a kind nod when he entered the room. The GP asked gently, “How are you doing?” and roughly 30 seconds passed (a long time in a conversation) before the patient spoke. “I just really miss her…” he whispered with great effort, “I don’t understand how this all happened.” Over the next 45 minutes, he spoke about his wife, how much pain she had been in, the rapid deterioration he witnessed, the cancer being found, and cruelly how she had passed away after he had gone home to get some rest after being by her bedside all day in the hospital. He talked about how they had met, how much he missed her, how empty the house felt without her, and asking himself and us how he was meant to move forward with his life. He had a lot of questions for us, and for himself. Had we missed anything – had he missed anything? The GP really just listened for almost the whole consultation, speaking to him gently, reassuring him that this wasn’t his or anyone’s fault. She stated that this was an awful time for him and that what he was feeling was entirely normal and something we will all universally go through. She emphasised that while it wasn’t helpful at the moment, that things would get better over time.3 He was really glad I was there – having shared a consultation with his wife and I – he thanked me emphatically even though I felt like I hadn’t really helped at all. After some tears, frequent moments of silence and a lot of questions, he left having gotten a lot off his chest. “You just have to listen to people, be there for them as they go through things, and answer their questions as best you can” urged my GP as we discussed the case when the patient left. Almost all family caregivers contact their GP with regards to grief and this consultation really made me realise how important an aspect of my practice it will be in the future.4 It has also made me reflect on the emphasis on undergraduate teaching around ‘breaking bad news’ to patients, but nothing taught about when patients are in the process of grieving further down the line.5 The skill Andrew MacFarlane Year 3 ScotGEM Medical Student 3 required to manage a grieving patient is not one limited to general practice. Patients may grieve the loss of function from acute trauma through to chronic illness in all specialties of medicine - in addition to ‘traditional’ grief from loss of family or friends.6 There wasn’t anything ‘medical’ in the consultation, but I came away from it with a real sense of purpose as to why this career is such a privilege. We look after patients so they can spend as much quality time as they are given with their loved ones, and their loved ones are the ones we care for after they are gone. We as doctors are the constant, and we have to meet patients with compassion at their most difficult times – because it is as much a part of the job as the knowledge and the science – and it is the part of us that patients will remember long after they leave our clinic room. Word Count: 993 words References 1. ScotGEM MBChB - Subjects - University of St Andrews [Internet]. [cited 2021 Mar 27]. Available from: https://www.st-andrews.ac.uk/subjects/medicine/scotgem-mbchb/ 2. Shared decision making in realistic medicine: what works - gov.scot [Internet]. [cited 2021 Mar 27]. Available from: https://www.gov.scot/publications/works-support-promote-shared-decisionmaking-synthesis-recent-evidence/pages/1/ 3. Ghesquiere AR, Patel SR, Kaplan DB, Bruce ML. Primary care providers’ bereavement care practices: Recommendations for research directions. Int J Geriatr Psychiatry. 2014 Dec;29(12):1221–9. 4. Nielsen MK, Christensen K, Neergaard MA, Bidstrup PE, Guldin M-B. Grief symptoms and primary care use: a prospective study of family caregivers. BJGP Open [Internet]. 2020 Aug 1 [cited 2021 Mar 27];4(3). Available from: https://bjgpopen.org/content/4/3/bjgpopen20X101063 5. O’Connor M, Breen LJ. General Practitioners’ experiences of bereavement care and their educational support needs: a qualitative study. BMC Medical Education. 2014 Mar 27;14(1):59. 6. Sikstrom L, Saikaly R, Ferguson G, Mosher PJ, Bonato S, Soklaridis S. Being there: A scoping review of grief support training in medical education. PLOS ONE. 2019 Nov 27;14(11):e0224325.